Toborzás még nem indult1/2. fázis
NEurotrophins Mimetic compound for the treatment of diabetic foot UlcerS
A legfontosabb adatok
- Ki végzi
- Mimetech S.r.l.
- Hol
- Olaszország5 helyszín, 1 országbanVálassz országot a helyszínekhez
- Állapot
- Toborzás még nem indult
- Fázis
- 1/2. fázis
- Résztvevők
- 24 fő, tervezett
- Kezdés
- 2021. júl. 1.
- Tervezett befejezés
- 2025. márc. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A regiszteradat frissítve
- 2025. szeptember 25.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with type 1 or 2 diabetes who have a foot ulcer that is not healing. It tests udonitrectag (MT8) added to standard care, compared with standard care alone.
- Életkor
- 18 years or older
- Nem
- Men and women
- A betegség stádiuma
- Diabetic foot wound grade I or II on the TEXAS scale, with infection grade 1 on the PEDIS scale. Ulcer area from 2 to 15 cm2. TpO2 >= 30 mmHg or ABI >= 0.70.
- Korábbi kezelés
- The ulcer has not healed with standard good care in the last 2-weeks (area shrank less than 20%). No other investigational product within 30 days before study treatment.
- Biomarker vagy leletérték
- HbA1c <=10% (or <= 86 mmol/mol). Women who can have children need a negative urine pregnancy test.
A részvétel fő kizáró okai
- Pregnant or breast-feeding women
- Autoimmune disease, weak immune system, or high-dose steroids or immunosuppressants
- Current smokers
- Severe kidney failure (eGFR< 30 ml/min), current cancer, or severe heart or liver disease
- Infected ulcer above grade 1, ulcer from other causes, or surgery or amputation planned during the study
A regiszter feltételei, szó szerint
Mind a 32 feltétel megnézéseKevesebb
Ki vehet részt
- Provision of signed and dated informed consent form
- Females of childbearing potential must have a negative urine pregnancy test prior to commencing the study
- Glycated haemoglobin (HbA1c) levels <=10% (or <= 86 mmol/mol)
- For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation
- For males with partners reproductive potential: use of condoms or other methods to ensure effective contraception with partner
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female
- Age >=18 years
- Diagnosis of type 1 or 2 diabetes mellitus
- A diabetic foot wound grade I or II, according to the TEXAS diabetic wound classification system and grading 1 in the PEDIS infection scale
- TpO2>= 30 mmHg or ABI (Ankle Brachial Index) >= 0.70
- Ulcers not healing with standard good care in the last 2-weeks (ulcer area reduction less than 20% versus baseline)
- Presence of ulcer with an area from 2 to 15 cm2 measured by MolecuLight i:XTM Wound Imaging Device
Ki nem vehet részt
- History of any medical or psychiatric conditions that, according to the Investigator, may increase the risks associated with the study’s participation or investigational product(s) administration
- Current use of high-dose steroids or immunosuppressants
- Participation in any other clinical trial or currently receiving any other investigational product(s) within 30 days prior to study treatment (Visit 1a o Visit 1b)
- Diagnosis of severe medical conditions such as severe heart failure or severe hepatic disease, according to the Investigator’s judgment or presence of concurrent illness indicating a short life expectancy
- Diagnosis of current of autoimmune disorders
- Patients with ulcers due to other etiologies (e.g., arterial insufficiency)
- Febrile illness within one month from Visit 1b
- Blood pressure above 180/100 or heart rate>100 bpm or Respiratory frequency >30
- Patients who show reductions or enlargement of the ulcer area >20% during the screening phase will not be enrolled for the study
- Presence of infected foot ulcer of grade >1 (according to the PEDIS diabetic foot ulcer classification system), diagnosed via a clinic examination
- Clinical diagnosis of peripheral vascular disease (PVD) requiring a prompt revascularization
- Any surgery planned in the study period, including scheduled amputation at the ulcer site
- Diagnosis of current cancer
- Patients with diabetes under poor control (HbA1c of >10% or >86 mmol/mol)
- Severe renal failure defined as eGFR< 30 ml/min
- Pregnancy or Lactation. Female patients who are pregnant or breast-feeding
- Immunosuppressed subjects
- Current smoker
- Childbearing potential female patients who do not agree to use an acceptable method of contraception during the study, providing they are not pregnant or lactating
Hol van ez a vizsgálat?
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To determine the safety, tolerability, and pharmacokinetic profile of udonitrectag (MT8) added to standard of care versus standard of care alone in the treatment of Diabetic Foot Ulcers.
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel az EU hivatalos vizsgálati nyilvántartásában (CTIS).
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
- A regiszteradat frissítve
- 2025. szeptember 25.